Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children
NCT07845994Phase 3Not yet recruiting
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Nov 2026
- Primary completion
- Feb 2031
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in hypothalamic obesity (HO), sponsored by Centre Hospitalier Universitaire d'Angers. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT07845994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07845994.